Waldsassen, 08.06.2021
In cooperation with the Administrative District Office, the Health Department, the BRK and some schools in the county of Tirschenreuth, the BioVariance laboratory recently started a pilot project for PCR testing of pupils and their teachers.
Waldsassen, 10.02.2021
BioVariance GmbH from Waldsassen gained the TOP 100 award 2021, which is given to highly innovative medium-sized companies once a year – now for the 28th time.
Waldsassen – BioVariance finishes the development of TubeLab, a software for the organisation of multi-level laboratory processes. To ensure an effective performance of the workflow, TubeLab was developed in cooperation with a renowned diagnostics laboratory.
Waldsassen – BioVariance has finished the development of the platform OncoVariant for the interpretation of genetic variants in cancer patients. Thereby, the crucial search for suitable drugs is simplified and accelerated significantly.
Waldsassen – BioVariance has received a commitment for the project REVERT from the European Commission as part of HORIZON 2020, the EU framework program for research and innovation.
DIPG (diffuse intrinsic pontine glioma) describes a brain tumor in children for which there exists no cure or positive life-changing treatment. Even if this type of pontine glioma can be classified as “rare diseases”,
Waldsassen – The statistic portal Statista and the business magazine „brand eins Innovation ist…“ have honored Germany’s most innovative companies for the fourth time.
Waldsassen/Munich. BioVariance GmbH, which is located in Waldsassen, took an important strategic step regarding the future orientation of the company by admitting two new partners. At the beginning of the year FlemingEnterprise Holding GmbH,
Waldsassen – The statistics portal “Statista” and the business magazine “brand eins Wissen” have selected Germany’s most innovative companies for the third time.
BioVariace has received a financial grant for a pioneering research project to calculate personalized dosages for psychotherapeutic drugs based on patient´s unique individual genetic biomarkers. The project “Knowledge for personalized medicine in psychiatric application” will be co-funded by the Bavarian Ministry of Economic Affairs and further project partners includes the Institute of Pharmacy of the University of Würzburg as well as the Center for Mental Health of the University Hospital of Würzburg.